Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Center for Humanistisk Sundhedsforskning

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

Fulltext
Forlagets udgivne version, 343 KB, PDF-dokument

Caroline Klint Johannesen
Gry St Martin
Maria Elisabeth Lendorf
Garred, Peter
Alexander Fyfe
Robert S. Paton
Craig Thompson
Mølsted, Stig
Caroline Elisabeth Kann
Claus Antonio Jensen
Hansen, Cecilie Bo
Løkkegaard, Ellen Christine Leth
Thomas Broe Christensen
Peter Simmonds
Fischer, Thea Kølsen

Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

Originalsprog	Engelsk
Artikelnummer	A11210843
Tidsskrift	Danish Medical Journal
Vol/bind	69
Udgave nummer	5
Antal sider	9
ISSN	2245-1919
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
Acknowledgements The authors would like to thank Camilla Xenia Holtermann Jahn,Mads Engelhardt Knudsen,SifKaas Nielsen, and Jytte Bryde Clausen from the Laboratory of Molecular Medicine at Rigshospitalet for their excellent technical assistance. We also thank Susanne Månsson, Charlotte Pietraszek and Anette Eva Anberg from the Clinical Research Unit, Nordsjællands Hospital, Capital Region, Denmark for excellency in implementation of the study and data management. This work was financially supported by grants from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201

Funding Information:
Funding. The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).

Funding Information:
The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201). The authors would like to thank Camilla Xenia Holtermann Jahn, Mads Engelhardt Knudsen, Sif Kaas Nielsen, and Jytte Bryde Clausen from the Laboratory of Molecular Medicine at Rigshospitalet for their excellent technical assistance. We also thank Susanne M?nsson, Charlotte Pietraszek and Anette Eva Anberg from the Clinical Research Unit, Nordsj?llands Hospital, Capital Region, Denmark for excellency in implementation of the study and data management. This work was financially supported by grants from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201.

Publisher Copyright:
© 2022, Almindelige Danske Laegeforening. All rights reserved.

Center for Humanistisk Sundhedsforskning